TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01885364

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal saline
Description: intravenous injection with normal saline before injection of propofol

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Esmolol
Description: intravenous injection with remifentanil 0.5 mg/kg before injection of propofol

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Esmolol
Description: intravenous injection with remifentanil 0.5 mg/kg before injection of propofol

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Remifentanil
Description: intravenous injection with remifentanil 0.35 ug/kg before injection of propofol

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: propofol
Description: intravenous injection after pretreatment

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: propofol
Description: intravenous injection after pretreatment

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: propofol
Description: intravenous injection after pretreatment

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: propofol
Description: intravenous injection after pretreatment
Study: NCT02435901

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: alemtuzumab (Campath IH)
Description: Alemtuzumab (Campath IH) is given daily over first 4 days, Day -20 to Day -17

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: Fludarabine 35/m2 is given daily over 4 days on Day -7 to Day -4.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Melphalan
Description: Melphalan 70mg/m2 is given daily over 2 days on Day -3 to Day -2.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclosporine
Description: Immunosuppressant to prevent graft vs host disease is given on Day -1 prior to stem cell infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mycophenolate mofetil
Description: Immunosuppressant to prevent graft vs host disease is given on Day -1.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tacrolimus
Description: Immunosuppressant to prevent graft vs host disease is given Day -1 prior to stem cell infusion

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Hematopoietic Stem Cell Transplantation
Description: Human Leukocyte Antigen (HLA) matched or mismatched; related or unrelated hematopoietic stem cells to be transplanted on Day 0.
Study: NCT01565161

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Home-Based Health Coaching
Description: The 6-month intervention arm consists of 3 components:~1. In-home coaching visits with a health educator trained in motivational interviewing to encourage behavior change. In addition to 4 monthly in-home coaching visits, participants receive 4 monthly coaching phone calls to supplement the in-person visits.~2. Use of mobile technology to deliver health information by text message - participants receive messages twice weekly for 16 weeks and then weekly for 8 weeks of the program. Those without a phone capable of receiving text messages receive postcards by mail.~3. Printed materials, including educational handouts, newsletters, and activities highlighting target behaviors, sent monthly for 4 months.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Mailed materials
Description: We designed materials for our control group focusing on Developmental milestones during early childhood to provide information that participants would find relevant and helpful for parenting, but that would also not influence intervention behaviors, such as TV viewing or household routines related to sleeping, eating, or television viewing.~Participants received 4 monthly mailing packages, each focusing thematically on one of four milestone domains: motor, language, cognitive and social/emotional. Educational materials were adapted from the Center for Disease Control's Positive Parenting Tips for Healthy Child Development, and the mailing included child-appropriate incentives to reinforce the concepts presented in the educational materials.
Study: NCT02943655

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: combined contraceptive pills (microcept)
Description: oral combined contraceptive once daily

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: medroxyprogesterone acetate (progest)
Description: oral 5 mg medroxyprogesterone acetate daily

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: mefenamic acid (ponstan forte)
Description: oral 500 mg mefenamic acid three times per day
Study: NCT02873884

Intervention type: BEHAVIORAL
Intervention: Case-management
Study: NCT03451643

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: ENDOSCOPIC PLACEMENT OF EXPANDABLE STENT
Description: PLACEMENT OF AN ENDOSCOPIC SELF EXPANDABLE METAL STENT

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: ENDOSCOPIC PLACEMENT OF EXPANDABLE STENT
Description: PLACEMENT OF AN ENDOSCOPIC SELF EXPANDABLE METAL STENT
Study: NCT02829073

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Device
Description: A placebo device, identical to the Neuromonics Oasis™ device with altered firmware will be fit to individuals reporting significant tinnitus. Assessment of primary and secondary measures will be made at 0 and 6 months following fitting.
Study: NCT01450878

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: beta-epoietin
Description: 100 000UI beta-epoietin injection one hour before organ retrieval
Study: NCT03152799

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: RIPC Remote Ischaemic Pre-Conditioning
Description: intermittent limb ischaemia via a peripheral blood pressure cuff inflation and deflation

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sham Control
Description: intermittent peripheral blood pressure cuff inflation and deflation which does not induce a protective cellular response
Study: NCT02793297

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: refined wheat crisp bread
Description: Refined wheat crisp bread (52 g) was served as part of a regular breakfast together with margarine (15 g), cheese (20 mg), coffee/tea (150 mL), and juice (150 mL). The amount of crisp bread was adjusted so that all arms provided a similar amount of available carbohydrate (35 g).

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: sourdough fermented rye crisp bread
Description: Sourdough fermented rye crisp bread (59.4 g) was served as part of a regular breakfast together with margarine (15 g), cheese (20 mg), coffee/tea (150 mL), and juice (150 mL). The amount of crisp bread was adjusted so that all arms provided a similar amount of available carbohydrate (35 g).

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: unfermented rye crisp bread
Description: Unfermented rye crisp bread (59.8 g) was served as part of a regular breakfast together with margarine (15 g), cheese (20 mg), coffee/tea (150 mL), and juice (150 mL). The amount of crisp bread was adjusted so that all arms provided a similar amount of available carbohydrate (35 g).
Study: NCT04439513

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Hemostasis
Description: Compression device to achieve hemostasis.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Hemostasis
Description: Compression device to achieve hemostasis.
Study: NCT01830166

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Low Dose Radiation Focal Brachytherapy
Description: Low Dose Radiation Focal Brachytherapy
Study: NCT03464071

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Hyperinflation with mechanical ventilator
Description: increase in initial positive inspiratory pressure until reaching a peak pressure of 40 cmH2O and PEEP equal to 7 cmH2O

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Manual hyperinflation
Description: the manual resuscitation bag will be connected to the oxygen system at five liters per minute. The participant will be disconnected from the ventilator and then initiate a slow inspiration with inspiratory pause followed by abrupt expiration, totaling twelve (12) cycles / minute.
Study: NCT03155282

Intervention type: PROCEDURE
Intervention: EUS-E to measure liver and spleen stiffness.
Description: The EUS-E quantitative evaluation will be performed on the left hepatic lobe transgastrically. For the SR calculation, the area A will be manually selected including as much of hepatic tissue as possible and the area B will be selected on the red gastric mucosa. For the strain histogram measurement, the ROI selected will have a surface of 60 mm2. The same procedure will be repeated 10 times at different points on the left hepatic lobe and finally the mean SR and SH values will be calculated. The same sequence will be repeated to measure the spleen stiffness. Finally the azygos vein (AV) will be evaluated using EUS Doppler. The mean velocity and the AV diameter will be measure and the AV blood flow volume index (BFVI) will be calculated.

Intervention type: PROCEDURE
Intervention: EUS-E to measure liver and spleen stiffness.
Description: The EUS-E quantitative evaluation will be performed on the left hepatic lobe transgastrically. For the SR calculation, the area A will be manually selected including as much of hepatic tissue as possible and the area B will be selected on the red gastric mucosa. For the strain histogram measurement, the ROI selected will have a surface of 60 mm2. The same procedure will be repeated 10 times at different points on the left hepatic lobe and finally the mean SR and SH values will be calculated. The same sequence will be repeated to measure the spleen stiffness. Finally the azygos vein (AV) will be evaluated using EUS Doppler. The mean velocity and the AV diameter will be measure and the AV blood flow volume index (BFVI) will be calculated.
Study: NCT04594343

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Disulfiram
Description: The subject will receive 500 mg of disulfiram orally or enterally through NG tube if in mechanical ventilation once daily for 14 days

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The subject will receive a matching placebo orally or enterally through NG tube if in mechanical ventilation once daily for 14 days
Study: NCT01284101

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Use of the Tan Endoglide to insert the donor graft
Description: Using the Tan Endoglide to insert the donor graft into the eye

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Forceps for delivery of the donor graft
Description: Use of the forceps for delivery of the donor graft into the eye.
Study: NCT01869439

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: gold standard LxW manual ruler measurement technique
Description: Currently, the gold standard LxW manual ruler measurement technique is used for measuring the area of an external wound. The LxW is measured by measuring the longest length (head to toe) times the widest width (perpendicular to the length).

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: WMMS ImageReview software's LxW measurement technique
Description: This software measurement technique is part of tthe WMMS and also measures the external wound LxW by the longest length (head to toe) times the widest width (perpendicular to the longest length).
Study: NCT00666939

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gabapentin
Description: Gabapentin 100 mg oral capsule 30 minutes prior to bedtime

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gabapentin
Description: Gabapentin 250 mg oral capsule 30 minutes prior to bedtime

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matched placebo 30 minutes prior to bedtime
Study: NCT00196365

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: levonorgestrel/EE 0.15/0.03 and EE 0.01 mg tablets
Description: 1 tablet daily

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: levonorgestrel/EE 0.15/0.03 mg tablets and placebo
Description: 1 tablet daily
Study: NCT03646669

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: PEF Feedback
Description: Patients in the PEF feedback arm will receive a one-time session including asthma management education, discussion of their asthma symptoms, review of individual PEF results and perception of symptoms, and problem-solving techniques to improve asthma self-management. After the session, the participants in this arm will be able to view in the display of the AM2 device their PEF values and will be instructed to mentally note their actual results with their pre-effort estimated BPF. They will also set a motivational message for themselves that will appear on the device.

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Asthma education
Description: General asthma education, AM2 training, and positive counseling, but no discussion linking asthma symptom perception to SMB. Following the session, these participants will use the AM2 to track PEF actual and perceived values twice per day, but they will be blinded to the actual PEF values. Control arm patients will see a standard motivational message appear on the screen of the AM2 device.
Study: NCT03085017

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: BoneSeal
Description: BoneSeal® is an absorbable synthetic bone hemostats that also contains of PLA, PEG and hydroxyapatite which supports bone re-growth. Product code MTJ. FDA number K142348.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Ostene
Description: OSTENE is a synthetic, biodissolvable implant material that, provides immediate bone hemostasis, can be used on all bleeding bone surfaces, is completely biocompatible and water-soluble polymer, is a mechanical barrier that does not act biochemically.
Study: NCT04483882

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Tactile Labels for Drug identity and dose frequency
Description: The tactile labeling proposed in this protocol is rigid labeling. A ring-clip has an inner diameter of 12.5cm, an outer diameter of 16 cm, and a height of 1.5 cm. The ring is cut at 2 cm to form a semi-circle allowing it to be clipped onto the bottleneck. The ring clip fits most if not all prescription eye drop bottles. The individual protrusions with shapes at the end can be cut off by the pharmacist to match the frequency of administration prescribed.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Tactile Labels for Drug identity and dose frequency
Description: The tactile labeling proposed in this protocol is rigid labeling. A ring-clip has an inner diameter of 12.5cm, an outer diameter of 16 cm, and a height of 1.5 cm. The ring is cut at 2 cm to form a semi-circle allowing it to be clipped onto the bottleneck. The ring clip fits most if not all prescription eye drop bottles. The individual protrusions with shapes at the end can be cut off by the pharmacist to match the frequency of administration prescribed.
Study: NCT01869439

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: WMMS ImageReview software's Visual External Wound Trace
Description: This is a measurement technique of the ImageReview software that enables the user to trace the perimeter edge of the wound's visual image.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: WMMS ImageReview software's External Wound Trace Overlay
Description: This measurement technique is a feature of the WMMS, utilizing the visual external wound trace and overlaying it onto the thermal wound site. From the thermal overlay, variation data such as the differences in the thermal intensities (gradient), mean, and the mode of the thermal wound bed can be measured.
Study: NCT05133752

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nemonoxacin
Description: 500 mg, oral administration, once daily for 7-10 days.
Study: NCT03172403

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Height and weight
Description: Height and weight will be measured to estimate cachexia degree at the time of anaesthetic consultation. (V1)

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Blood samples
Description: Blood samples will be collected for measuring myostatin on blood at the time of anaesthetic consultation, the day before resection surgery, follow-ups at 1, 3 and 6 months. (V1, V2, V3, V4, V6)

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Skeletal muscle force
Description: Skeletal muscle force will be determined from Computerized Tomography (CT)-scan at the time of anaesthetic, follow-ups at 1, 3 and 6 months. (V1, V3, V4, V6)

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Skeletal muscle index
Description: Skeletal muscle index will be determined from Computerized Tomography (CT)-scan at the time of anaesthetic, follow-ups at 1, 3 and 6 months. (V1, V3, V4, V6)

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Muscle biopsy
Description: Muscle biopsy will be performed during resection surgery under general anaesthesia. (V2)
Study: NCT03380975

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Montelukast 10mg
Description: Montelukast is an orally active compound which binds with high affinity and selectivity to the CysLT1 receptor. Montelukast inhibits physiologic actions of LTD4 at the CysLT1 receptor without any agonist activity. As a result, bronchoconstriction is inhibited with decreased airway and blood eosinophil's leading to improved control over asthma and allergic rhinitis. Montelukast should be taken once daily in the evening
Study: NCT04928872

Intervention type: COMBINATION_PRODUCT
Intervention: Predefined meal
Description: Nine predefined meals are administered in a randomized fashion, one meal per one study day, 2-3 study days per week. Meals have a form of drinks with different compositions of protein, carbohydrates and fat in relation to the US diet
Study: NCT00370448

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: school-based social support system
Description: Training gatekeeper recruited from students and tutors and counselors for group 1; training counsellors for group 2; No special intervention for group 3

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: school-based social support system
Description: Training gatekeeper recruited from students and tutors and counselors for group 1; training counsellors for group 2; No special intervention for group 3

Intervention type: BEHAVIORAL
Group type: NO_INTERVENTION
Intervention: school-based social support system
Description: Training gatekeeper recruited from students and tutors and counselors for group 1; training counsellors for group 2; No special intervention for group 3
Study: NCT02831114

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Acupuncture
Description: Acupuncture uses tiny needles to promote blood flow, nervous system signaling, and brings the body back into homeostasis which the state of optimum functioning. Treatment for taxane induced peripheral neuropathy will consist of traditional acupuncture and will use points located in the foot (SP 3, ST 41, LR 3, K 3, GB 41), knee (SP 9, ST 36, K 10, GB 34), and arm (LI 11). Participants will continue to take their conventional therapy. Each acupuncture treatment will take place at Oriental Medicine Associates with trained acupuncturist, William Hendry. Each session should last about 30 minutes.
Study: NCT02877199

Intervention type: OTHER
Intervention: Triple therapy
Description: Cohort of patients who received triple therapy combining pegylated-interferon/ribavirin + first generation protease inhibitor boceprevir or telaprevir as part of routine clinical practice
Study: NCT01188629

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Safety Training
Description: IT intervention focuses on safety in the home.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Personal Health Partner and Counseling (PHP+C)
Description: The PHP intervention will have three primary functional areas: 1) pre-visit assessment and counseling; 2) EHR data exchange with clinician review; and 3) post-visit follow-up, re-assessment, and counseling.
Study: NCT00364442

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fluticasone propionate/salmeterol
Description: investigational drug
Study: NCT03681691

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Estradiol patch
Description: transdermal 17β-estradiol patch

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Estradiol patch
Description: transdermal 17β-estradiol patch
Study: NCT01516892

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: onabotulinumtoxinA
Description: Participants received 155 U of onabotulinumtoxinA approximately every 12 weeks for 108 weeks. OnabotulinumtoxinA was administered as 31 intramuscular injections in 7 head/neck muscle areas.
Study: NCT01360190

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: fluoxetine
Description: fluoxetine 20 mg. daily

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: fluoxetine
Description: fluoxetine 20 mg. daily
Study: NCT03155490

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Leadership training
Description: Subjects randomized to the experimental arm of the study will receive an additional 4 hours of simulation-based trauma team leadership training. This training is in addition to the baseline 2 hours of trauma leader training and orientation all subjects receive.
Study: NCT00938340

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Walnut meat
Description: Separated, ground walnut de-fatted nut meat incorporated into inert food carrier

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Walnut Oil
Description: Walnut oil extracted from nut meat and incorporated into inert food carrier

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Walnut Skins
Description: Separated, ground walnut skins incorporated into inert food carrier

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Whole walnut
Description: 85g whole walnuts, ground, incorporated into inert food carrier
Study: NCT05163756

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DW1903
Description: q.d. PO, DW1903 + Placebo of DW1903-R1

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: DW1903-R1
Description: q.d. PO, Placebo of DW1903 + DW1903-R1
Study: NCT02334306

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AMG 557/MEDI5872
Description: Participants will receive a fixed SC dose of 210 mg MEDI5872 (AMG 557/MEDI5872) QW for 3 weeks (Days 1 to 15) and then Q2W for 9 weeks (Days 29 to 85) in double-blind period of the study. In open-label period, all participants from double-blind period will receive a fixed SC dose of 210 mg MEDI5872 from Day 99 to Day 183 (QW from Days 99 to 113 for participants from Placebo arm and on Days 99 and 113 for participants from MEDI5872 210 mg arm; and Q2W from Days 127 to 183 for participants from both arms).

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The SC dose of placebo every week for 3 weeks (Days 1 to 15) and then every 2 weeks for 9 weeks (Days 29 to 85) in double-blind period of the study. In open-label period, an additional dose of blinded placebo will be administered on Day 106 for participants who will receive MEDI5872 210mg in double-blinded period.
Study: NCT02374203

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: high protein enteral nutrition
Description: supply protein over 1.5 gm/kg body weight